Literature DB >> 8281619

Combined oral administration of etoposide and arabinofuranosylcytosine-5'-stearylphosphate enhances the antitumor effect against P388 ascites tumors.

M Higashigawa1, D C Cao, K Matsui, S Yamada, H Kakitou, Y Kagawa, H Inamochi, M Ido, M Sakurai.   

Abstract

We investigated the antitumor effect of oral administration of etoposide and arabinofuranosylcytosine-5'-stearylphosphate (C18PCA) against P388 ascites tumors in B6D2F1 mice. Etoposide (25 mg/kg) and C18PCA (5 mg/kg) were given orally on days 1-5 after tumor inoculation. The median life span of the mice treated with etoposide or C18PCA alone was 19.5 and 18 days, respectively. The combination of both drugs significantly extended the median life span to 33 days. To clarify this enhancement of the increase in median life span, we examined intracellular deoxyribonucleoside triphosphate (dNTP) pools, cell-cycle distribution, DNA fragmentation, and the time course of the plasma drug concentration. Etoposide had no effect on intracellular dNTP pools in this experimental system, whereas treatment of cells with C18PCA or with the combination of both drugs resulted in a significant increase in dTTP pools to values ranging from 1.8- to 2.0-fold higher than the control levels. There was a significant increase in cells in the S + G2/M phase when cells had been treated with both etoposide and C18PCA. Agarose-gel electrophoresis of the extracted DNA revealed that C18PCA enhanced the fragmentation of DNA, with a length of about 180 bp being induced by etoposide. The plasma peak levels of etoposide (1000 nM) and ara-C (50 nM) were observed at 20 and 30 min after the simultaneous administration of both drugs, respectively. The plasma etoposide level gradually decreased to 10% of the peak level at 240 min after administration. On the other hand, the plasma concentration of ara-C was maintained at above 20 nM at 240 min. These observations suggest that C18PCA and etoposide act on P388 murine leukemic cells by accumulating cells in the S + G2/M phase. Even if the plasma concentration of ara-C is low, the repair of DNA damage by etoposide may be hindered in the presence of ara-C following an increase in DNA fragmentation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8281619     DOI: 10.1007/BF00685900

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  34 in total

1.  Decreased DNA polymerase sensitivity to 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in P388 murine leukemic cells resistant to vincristine.

Authors:  M Higashigawa; M Ido; Y Nagao; H Kuwabara; H Hori; T Ohkubo; H Kawasaki; M Sakurai
Journal:  Leuk Res       Date:  1991       Impact factor: 3.156

2.  Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial.

Authors:  D H Johnson; F A Greco; J Strupp; K R Hande; J D Hainsworth
Journal:  J Clin Oncol       Date:  1990-10       Impact factor: 44.544

3.  Increased sensitivity to 1-beta-D-arabinofuranosylcytosine in P388 murine leukemic cells resistant to etoposide.

Authors:  M Higashigawa; M Ido; T Ohkubo; H Kawasaki; H Kamiya; M Sakurai; K Taniguchi; M Hamazaki
Journal:  Leuk Res       Date:  1989       Impact factor: 3.156

4.  [Sensitivity to etoposide in cultured cells from cervical squamous cell carcinoma].

Authors:  T Maeda; M Ueda; T Yamada; H Kubo; S Okamura; T Sano; M Ueki; O Sugimoto
Journal:  Nihon Sanka Fujinka Gakkai Zasshi       Date:  1986-11

5.  Enhanced incorporation of 1-beta-D-arabinofuranosylcytosine by pretreatment with etoposide.

Authors:  K Ooi; T Ohkubo; H Kuwabara; M Higashigawa; H Kawasaki; H Kakitoh; Y Kagawa; S Inagaki; K Sumida; M Sakurai
Journal:  Cancer Invest       Date:  1993       Impact factor: 2.176

6.  Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship.

Authors:  B H Long; S T Musial; M G Brattain
Journal:  Biochemistry       Date:  1984-03-13       Impact factor: 3.162

7.  [Low dose continuous infusion therapy with etoposide (VP-16) and cytosine arabinoside (Ara-C) for a patient with refractory acute myelogenous leukemia].

Authors:  S Koyama; S Itou; A Shibata
Journal:  Rinsho Ketsueki       Date:  1990-11

8.  Sequence-dependent antitumor effect of VP-16 and 1-beta-D-arabinofuranosylcytosine in L1210 ascites tumor.

Authors:  T Ohkubo; M Higashigawa; H Kawasaki; H Kamiya; M Sakurai; Y Kagawa; E Kakito; K Sumida; K Ooi
Journal:  Eur J Cancer Clin Oncol       Date:  1988-12

9.  Sensitive radioimmunoassay for cytarabine and uracil arabinoside in plasma.

Authors:  T Sato; M Morozumi; K Kodama; A Kuninaka; H Yoshino
Journal:  Cancer Treat Rep       Date:  1984-11

10.  Antitumor activity and pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate: an orally active derivative of 1-beta-D-arabinofuranosylcytosine.

Authors:  K Kodama; M Morozumi; K Saitoh; A Kuninaka; H Yoshino; M Saneyoshi
Journal:  Jpn J Cancer Res       Date:  1989-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.